Compare AIN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | NRIX |
|---|---|---|
| Founded | 1895 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | AIN | NRIX |
|---|---|---|
| Price | $57.80 | $15.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $60.25 | $29.46 |
| AVG Volume (30 Days) | 211.6K | ★ 844.9K |
| Earning Date | 06-01-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,054,132,000.00 | $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.29 | ★ 99.31 |
| 52 Week Low | $41.15 | $8.18 |
| 52 Week High | $80.71 | $22.50 |
| Indicator | AIN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 42.26 |
| Support Level | $51.37 | $15.62 |
| Resistance Level | $53.88 | $19.98 |
| Average True Range (ATR) | 2.08 | 0.78 |
| MACD | -0.41 | -0.03 |
| Stochastic Oscillator | 2.41 | 36.46 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.